{"log_id": 6013803687623211101, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 0.000455, "average": 0.994236, "min": 0.878886}, "location": {"width": 727, "top": 228, "height": 40, "left": 277}, "words": "尚不知达托霉素是否能够分泌至人乳中。因为许多药物会分泌至人乳汁中"}, {"probability": {"variance": 0.00014, "average": 0.994779, "min": 0.95677}, "location": {"width": 274, "top": 273, "height": 32, "left": 230}, "words": "因此哺乳期妇女应慎用本品"}, {"probability": {"variance": 0.030209, "average": 0.908594, "min": 0.561056}, "location": {"width": 127, "top": 326, "height": 28, "left": 236}, "words": "儿童用药〗"}, {"probability": {"variance": 3.5e-05, "average": 0.997373, "min": 0.971522}, "location": {"width": 534, "top": 370, "height": 38, "left": 273}, "words": "尚未在18岁以下的患者中确立本品的安全性和有效性"}, {"probability": {"variance": 0.005138, "average": 0.961912, "min": 0.802749}, "location": {"width": 128, "top": 414, "height": 29, "left": 232}, "words": "〖老年用药〗"}, {"probability": {"variance": 0.003113, "average": 0.981614, "min": 0.721229}, "location": {"width": 747, "top": 451, "height": 41, "left": 271}, "words": "在复杂性皮肤及软组织感染( CSSSI)的Ⅲ期对照临床试验中,534例患者"}, {"probability": {"variance": 0.000357, "average": 0.995606, "min": 0.882124}, "location": {"width": 791, "top": 495, "height": 41, "left": 224}, "words": "接受本品治疗,其中27%的患者年龄为65岁或以上,12%的患者年龄为75岁或"}, {"probability": {"variance": 0.000261, "average": 0.994592, "min": 0.921142}, "location": {"width": 790, "top": 539, "height": 41, "left": 225}, "words": "以上。在金黄色葡萄球菌菌血症/心内膜炎的期对照临床试验中,120例患者"}, {"probability": {"variance": 0.000335, "average": 0.994702, "min": 0.886907}, "location": {"width": 792, "top": 583, "height": 42, "left": 223}, "words": "接受本品治疗,其中25%的患者年龄为65岁或以上,16%的患者年龄为75岁或"}, {"probability": {"variance": 0.004443, "average": 0.981787, "min": 0.629237}, "location": {"width": 790, "top": 627, "height": 42, "left": 224}, "words": "以上。在 CSSSI和金黄色葡萄球菌菌血症/心内膜炎的Ⅲ期临床试验中,与年龄"}, {"probability": {"variance": 3.5e-05, "average": 0.997501, "min": 0.966875}, "location": {"width": 791, "top": 672, "height": 42, "left": 221}, "words": "小于65岁的患者相比,年龄≥65岁的患者的临床有效率较低。另外,与年龄小"}, {"probability": {"variance": 3e-06, "average": 0.998651, "min": 0.991372}, "location": {"width": 726, "top": 716, "height": 42, "left": 220}, "words": "于65岁的患者相比,在年龄≥65岁的患者中更常在治疗中出现不良事件"}, {"probability": {"variance": 5.3e-05, "average": 0.996604, "min": 0.963864}, "location": {"width": 746, "top": 761, "height": 43, "left": 266}, "words": "健康老年受试者的达托霉素暴露剂量大于健康年轻受试者的达托霉素暴露"}, {"probability": {"variance": 0.000338, "average": 0.990655, "min": 0.921787}, "location": {"width": 794, "top": 806, "height": 42, "left": 217}, "words": "剂量。然而,在肌酐清除率(CLc)≥30mL/min的老年患者中没有调整本品使用"}, {"probability": {"variance": 1e-06, "average": 0.999148, "min": 0.997059}, "location": {"width": 116, "top": 851, "height": 27, "left": 218}, "words": "剂量的依据"}, {"probability": {"variance": 0.000108, "average": 0.992629, "min": 0.965727}, "location": {"width": 177, "top": 902, "height": 28, "left": 224}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.013489, "average": 0.951498, "min": 0.587657}, "location": {"width": 520, "top": 939, "height": 38, "left": 260}, "words": "1、羟甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂"}, {"probability": {"variance": 4.7e-05, "average": 0.996426, "min": 0.970977}, "location": {"width": 748, "top": 983, "height": 42, "left": 261}, "words": "在健康受试者中,本品和辛伐他汀联合给药对辛伐他汀的血浆谷浓度没有影"}, {"probability": {"variance": 0.000267, "average": 0.993249, "min": 0.918999}, "location": {"width": 780, "top": 1028, "height": 42, "left": 216}, "words": "响,而且没有导致骨骼肌病的报告。但是, HMG COA还原酶抑制剂可能引起肌病"}, {"probability": {"variance": 0.002864, "average": 0.982058, "min": 0.708598}, "location": {"width": 794, "top": 1072, "height": 43, "left": 214}, "words": "表现为与肌酸磷酸激酶(CPK)水平升高相关的肌痛和肌无力。在Ⅲ期金黄色葡"}, {"probability": {"variance": 0.010738, "average": 0.973084, "min": 0.396516}, "location": {"width": 794, "top": 1115, "height": 45, "left": 214}, "words": "萄球菌菌血症/心内膜炎试验中,之前或伴随使用HMG-CA还原酶抑制剂的患者接"}, {"probability": {"variance": 0.006957, "average": 0.980518, "min": 0.468478}, "location": {"width": 794, "top": 1161, "height": 42, "left": 213}, "words": "受本品治疗时CPK水平升高。由于HMG-CoA还原酶抑制剂与本品伴随用药在患者中"}, {"probability": {"variance": 0.000164, "average": 0.996069, "min": 0.925369}, "location": {"width": 796, "top": 1204, "height": 46, "left": 211}, "words": "的应用经验有限,因此,对于正暂时接受本品治疗的患者,应考虑停止使用"}, {"probability": {"variance": 0.010469, "average": 0.952564, "min": 0.710116}, "location": {"width": 222, "top": 1252, "height": 31, "left": 212}, "words": "HMG-CoA还原酶抑制剂"}, {"probability": {"variance": 5.7e-05, "average": 0.996308, "min": 0.970544}, "location": {"width": 315, "top": 1296, "height": 34, "left": 255}, "words": "2、药物一实验室检查相互作用"}, {"probability": {"variance": 0.000352, "average": 0.99422, "min": 0.894283}, "location": {"width": 748, "top": 1341, "height": 41, "left": 256}, "words": "研究已经发现,当某些重组促凝血酶原激酶药物用于该试验时,达托霉素的"}, {"probability": {"variance": 1.8e-05, "average": 0.998056, "min": 0.976883}, "location": {"width": 795, "top": 1384, "height": 43, "left": 209}, "words": "临床相关血浆浓度可引起明显的浓度依赖性的虚假凝血酶原时间(PT)延长及国"}, {"probability": {"variance": 5.1e-05, "average": 0.996402, "min": 0.96322}, "location": {"width": 795, "top": 1429, "height": 42, "left": 208}, "words": "际标准化比值(INR)升高。由于达托霉素与重组促凝血酶原激酶药物间的相互"}, {"probability": {"variance": 0.000295, "average": 0.992272, "min": 0.935072}, "location": {"width": 798, "top": 1473, "height": 44, "left": 206}, "words": "作用,可能会导致一种错误的PT/INR升高的结果,而采用以下方法可使这种错误"}, {"probability": {"variance": 0.00012, "average": 0.995847, "min": 0.935491}, "location": {"width": 794, "top": 1518, "height": 43, "left": 207}, "words": "的可能性最小化,即在接近达托霉素波谷血浆浓度时采样进行PT或INR测试。但"}], "language": 3}